KOSDAQMedia & Entertainment086980

Showbox

₩1,748▼ 0.29%2026-10-02 close

Market Cap

₩108.1B

Turnover

₩100M

Volume

70,000 shares

Shares out.

62.4M

PER

6.1×

PBR

0.9×

EPS

₩322

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Showbox Swings to Profit on 'The Man Who Lives With the King'

Boosted by the record-breaking box office run of 'The Man Who Lives With the King,' Showbox posted a sharp turnaround in first-half 2026 results, though reliance on a single title and structural risks in the theatrical industry remain unresolved challenges.

1
Released in February 2026, 'The Man Who Lives With the King' topped the first-quarter box office with 151.8 billion won in revenue and 15.73 million admissions, driving Showbox's results.
2
As a result, first-quarter 2026 revenue reached 78.8 billion won with 21.7 billion won operating profit, followed by 67.6 billion won revenue and 12.5 billion won operating profit in the second quarter, extending profitability for two consecutive quarters.
3
In the prior year 2025, the company swung to an operating loss of 11.7 billion won on revenue of 62.7 billion won, mainly due to the absence of a major hit film.
4
Orion Holdings, the controlling shareholder, holds a 57.47% stake, with Showbox serving as the content arm of Orion Group's non-food portfolio.
5
In June 2026, JoongAng Group affiliates including Megabox Joongang (which owns Plus M Entertainment) filed for court receivership, adding uncertainty to the broader theatrical industry infrastructure.

Business structure

Founded in 1999, Showbox's core business is film investment and distribution, and since 2020 the company has expanded into drama and OTT series planning and production. Based on past disclosures, the film segment accounted for roughly half of revenue with production and sales the next largest contributor.

Flagship distributed titles include 'Exhuma' and 'The Man Who Lives With the King,' and the company has backed multiple Korean films that surpassed ten million admissions since 2004.

In dramas, Showbox entered the production market with 'Itaewon Class,' and more recently 'The Witch' achieved strong ratings on Channel A and ranked highly on Netflix, while the company signed a drama production deal with The Walt Disney Company to expand its business.

Competitively, Showbox sits alongside major domestic investor-distributors such as CJ ENM, Lotte Entertainment, NEW, and Plus M Entertainment under Megabox Joongang.

Orion Holdings, holding a 57.47% stake, is the controlling shareholder, positioning Showbox as the non-food, content-focused arm within the confectionery-centered Orion Group.

Revenue and profit show significant year-to-year volatility depending on box-office outcomes, reflecting an investment-distribution business model in which the success or failure of one or two tentpole films can determine annual results.

Recently, the company has pursued a strategy of reducing the number of titles while concentrating investment on tentpole films, staggering release dates to avoid its own titles competing against each other.

Earnings trend

Quarterly revenue · Operating profit

₩18.9B-₩5.5B25Q2₩17.3B-₩1.2B25Q3₩14.8B-₩3.6B25Q4₩78.9B₩21.7B26Q1₩67.6B₩12.5B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩56.7B-₩3.2B2022₩40.2B-₩28.3B2023₩93.1B₩24.5B2024₩62.7B-₩11.7B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩18.9B	-₩5.5B	−29.0%
2025Q3	₩17.3B	-₩1.2B	−6.9%
2025Q4	₩14.8B	-₩3.6B	−24.1%
2026Q1	₩78.9B	₩21.7B	27.5%
2026Q2	₩67.6B	₩12.5B	18.5%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩56.7B	-₩3.2B	-₩2.1B	−5.6%	−1.6%	20.7%
2023	₩40.2B	-₩28.3B	-₩30.3B	−70.4%	−28.9%	25.9%
2024	₩93.1B	₩24.5B	₩27.4B	26.3%	20.7%	16.5%
2025	₩62.7B	-₩11.7B	-₩15B	−18.6%	−14.0%	23.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23

Earnings analysis

Looking at annual results, revenue was 56.7 billion won with an 3.2 billion won operating loss in 2022, and losses widened in 2023 to a 28.3 billion won operating loss on 40.2 billion won revenue, before the company turned profitable in 2024 with 93.1 billion won revenue and 24.5 billion won operating profit, driven by the box-office success of 'Exhuma.' In 2025, however, revenue declined to 62.7 billion won and the company swung back to an 11.7 billion won operating loss and a 15.0 billion won net loss, largely because no film of comparable scale to the prior year's hit was released.

On a quarterly basis, operating losses persisted for four straight quarters: 18.9 billion won revenue with a 5.5 billion won operating loss in the second quarter of 2025, 17.3 billion won revenue with a 1.2 billion won operating loss in the third quarter, and 14.8 billion won revenue with a 3.6 billion won operating loss in the fourth quarter.

The trend reversed sharply in the first quarter of 2026, with revenue of 78.8 billion won, operating profit of 21.7 billion won, and net income attributable to owners of 17.9 billion won, reflecting the substantial box-office revenue recognized from 'The Man Who Lives With the King.' Profitability continued into the second quarter with 67.6 billion won revenue, 12.5 billion won operating profit, and 9.8 billion won net income attributable to owners, showing that the box-office effect extended across two quarters rather than being a one-off.

Over the most recent four quarters (third quarter 2025 through second quarter 2026), net income attributable to owners totaled approximately 20.1 billion won, marking a clear departure from the 2025 annual loss.

That said, the extent to which this profit recovery depends on the outsized success of a single title is a factor worth weighing when assessing the sustainability of future earnings.

Industry analysis

In the first quarter of 2026, total domestic theater revenue reached 318 billion won with 31.9 million admissions, the highest first-quarter figures since the pandemic year of 2020.

Most of this recovery was driven by a single film, 'The Man Who Lives With the King,' with Showbox-distributed titles accounting for 57.1% of total first-quarter admissions.

Looking at the first half as a whole, the top-grossing 'The Man Who Lives With the King' accounted for 45% of the 37.37 million admissions for Korean films, with a gap of more than 11 million admissions over the second-place film, indicating that the market recovery was concentrated in a single title rather than spread evenly.

Among distributors, Showbox topped the ranking with first-half revenue of 281.4 billion won and a 48.6% market share, of which a single film, 'The Man Who Lives With the King,' accounted for 58%.

Structurally, however, admissions decline and reduced investment across the industry persist, and major investor-distributors continue to trim the number of titles in their lineups and grow more cautious about tentpole investments.

Notably, in June 2026 Megabox Joongang, the parent of competing distributor Plus M Entertainment, filed for court receivership alongside other JoongAng Group affiliates, spreading uncertainty across theater infrastructure, including settlement disputes with commissioned theaters.

While this is not a direct financial issue for Showbox, it is cited as a risk to the stability of the broader theatrical distribution ecosystem.

Although Showbox has relatively strengthened its presence as competitors' investment and distribution activity has weakened, the broader structural shift toward fewer distributors capable of reliably backing mid-to-large Korean films is also worth monitoring.

Outlook

For 2026, Showbox has confirmed a lineup following 'The Man Who Lives With the King' that includes director Yeon Sang-ho's 'Gunchae,' director Lee Sang-min's horror film 'Salmokji,' and the psychological thriller 'Blizzard' starring Kim Yoon-seok and Gu Kyo-hwan.

'Salmokji,' released in April, had drawn 2.13 million admissions and 21.9 billion won in box-office revenue as of April 29, while 'Gunchae,' released in the second quarter, ranked second in first-half admissions with 5.74 million viewers.

'Blizzard,' co-directed by Hong Ui-jeong and Park Sun-woo and slated for a year-end release, is positioned as a key title for the second-half lineup.

In the drama and production segment, 'The Witch' performed well on Channel A and on Netflix's rankings, and the company is pursuing revenue diversification through a drama production agreement with The Walt Disney Company.

That said, funding constraints and reduced investment persist across the film industry broadly, with major investor-distributors confirming far fewer lineup titles than during past boom periods.

Management has indicated it will continue a strategy of reducing the number of titles while concentrating on tentpole films and staggering release timing, while continuing to pursue content portfolio diversification through overseas investment and synergy with the Orion brand.

Valuation

PER

6.1×

PBR

0.9×

ROE

16.1%

EPS

₩322

BPS

₩2,164

Dividend per share

₩0

The return to profitability over the past two quarters has once again tested how the market values the company's earnings, with the share price reacting sensitively whenever box-office results are confirmed.

Looking across multiple years, the company has moved between loss and profit repeatedly, and this latest recovery follows that same pattern, reflecting the earnings volatility inherent to the hit-driven investment-and-distribution business model.

The share price relative to net asset value is a useful reference point when compared against prior periods of profitability, and dividends—resumed following the 2024 earnings recovery—have again become uncertain following the return to a loss in 2025.

How the market judges valuation going forward is likely to hinge on whether the second-half lineup performs well at the box office and on whether the broader theatrical industry recovery proves durable.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23

Bull factors

Dominant distributor position and box-office track record

Showbox held the top domestic distributor position with a 48.6% revenue share in the first half of 2026, and 'The Man Who Lives With the King' became the all-time top-grossing domestic release.

The track record of distributing major hits in even-numbered years—'Exhuma' in 2024 and 'The Man Who Lives With the King' in 2026—is cited as a positive factor. This hit-making capability could also serve as leverage in future investment fundraising or production partnerships.

Diversification into production and IP licensing

Beyond film distribution, Showbox has expanded into drama and OTT series planning and production. 'The Witch' performed well on Channel A and on Netflix's rankings, and the company signed a drama production agreement with The Walt Disney Company. This could help reduce long-term dependence on the success of any single film.

Potential relative benefit from weakened competitors

With competing distributor Plus M Entertainment's parent, Megabox Joongang, entering court receivership, there is a possibility that the pool of distributors capable of reliably backing large-scale Korean films could shrink. In this environment, Showbox is seen as relatively strengthening its presence. However, this needs to be weighed against the broader decline in industry stability that accompanies it.

Bear factors

Earnings structure heavily reliant on a single title

A single title, 'The Man Who Lives With the King,' accounted for 58% of Showbox's 281.4 billion won in first-half 2026 revenue. In 2025, without a comparable hit, revenue declined and the company posted operating losses for four consecutive quarters.

Under this structure, earnings could swing significantly again depending on whether the next tentpole film succeeds.

Uncertainty in theatrical industry infrastructure

In June 2026, JoongAng Group affiliates including Megabox Joongang, the parent of a competing distributor, filed for court receivership, triggering disruptions across theater infrastructure including settlement disputes with commissioned theaters.

If the stability of theatrical exhibition networks is shaken, it could indirectly affect distribution schedules and revenue collection. Restoring confidence across the industry as a whole is likely to take time.

Ongoing production funding and investment contraction

Across the Korean film industry, admissions decline and investment contraction persist, with major investor-distributors having sharply reduced the number of lineup titles compared to past boom periods and growing more cautious even about partial investments.

In this environment, the investment risk associated with any single tentpole film can be relatively larger. The possibility of delays in funding or release schedules for upcoming titles cannot be ruled out.

Risk factors

Box-office volatility risk

Film investment and distribution is inherently characterized by large swings in revenue and profit depending on individual titles' box-office success or failure. The alternating losses in 2023 and 2025 and profit turnarounds in 2024 and 2026 illustrate this structure well. Future results could again fluctuate significantly depending on how upcoming lineup titles perform.

Theater infrastructure and counterparty risk

The court receivership of JoongAng Group affiliates, including Megabox Joongang, the parent of a competing distributor, has caused disruptions in theater settlement systems and the operation of commissioned theaters.

While Showbox is not directly party to this debt, the resulting erosion of confidence across the theatrical distribution network is cited as a risk that could indirectly affect release schedules and box-office performance.

Production cost and expense risk

A tentpole-focused investment strategy can result in larger per-title production budgets. For instance, the zombie film 'Gunchae' reportedly required a production budget approaching 20 billion won. Should such a film underperform at the box office, the structure could lead to substantial impairment or losses.

What to watch next

During the fourth quarter of 2026 (year-end)
Check the release and early box-office performance of the psychological thriller 'Blizzard' (starring Kim Yoon-seok and Gu Kyo-hwan). The success or failure of the second-half lineup is a key variable for the annual results direction.
Around November 2026
Around the time of the third-quarter 2026 earnings disclosure, check whether the box-office effect of 'The Man Who Lives With the King' has continued and how much revenue from follow-up titles has been recognized.
Ongoing monitoring of Megabox Joongang's receivership progress
Continue monitoring the progress of Megabox Joongang's court receivership—the parent of competing distributor Plus M Entertainment—and whether settlement issues with commissioned theaters are resolved. This is directly tied to the stability of theater infrastructure.
Upon next dividend-related disclosure
Since the 2025 loss has left dividends uncertain, future disclosures should be checked to see whether the 2026 earnings recovery leads to a resumption of dividend payments.

Overall view

Buoyed by the record-breaking box-office run of 'The Man Who Lives With the King,' Showbox posted consecutive profits in the first and second quarters of 2026, marking a clear departure from the loss-making conditions of 2025.

Net income attributable to owners over the most recent four quarters totaled approximately 20.1 billion won, a notable recovery compared with the prior year's annual net loss of 15.0 billion won.

However, this recovery relied heavily on a single title that accounted for 58% of first-half revenue, and the business retains a structure in which results could swing sharply again in a year without a major hit, as seen in 2025.

On the industry side, the court receivership of Megabox Joongang, the parent of a competing distributor, has added uncertainty across theater infrastructure more broadly, a factor that also warrants attention.

Going into the second half, the box-office performance of upcoming titles such as 'Blizzard,' the durability of the broader theatrical industry recovery, and whether dividends resume are likely to be key points to watch in gauging future earnings and shareholder return direction.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.